Data demonstrate efficacy of more flexible dose of regorafenib to relieve side-effects in mCRC patients

Medical oncologists administer anticancer drug regorafenib to try to improve overall survival in patients with metastatic colorectal cancer who have ceased to respond to standard therapy (known as refractory mCRC). However, some of the adverse events related to the use of this drug often limits its use in clinical practice. A study reported at the ESMO World Congress on Gastrointestinal Cancer 2019 suggests the usefulness of a more flexible dosing, which improves patients' quality of life without jeopardising efficacy. (1,2)

source https://www.lifetechnology.com/blogs/life-technology-news-blog/data-demonstrate-efficacy-of-more-flexible-dose-of-regorafenib-to-relieve-side-effects-in-mcrc-patients